In addition, fucoxanthin reportedly has anti-obesity and anti-diabetic effects. It has attracted much attention from the food industry and from nutrition researchers because of the unique mechanism of these effects. These effects are specific for fucoxanthin: they have not been found for other carotenoids such as β-carotene and astaxanthin. Furthermore, fucoxanthin enhanced the amount of DHA in the liver of mice. This review describes unique bioactivity of fucoxanthin in brown algae.
coupling protein 1 UCP1 in abdominal WAT. Reduction of WAT weight using fucoxanthin and lipid extract of algae containing fucoxanthin has been reported in an obesity model mouse, specifically with high-calorie-diet-induced obesity model mouse experiments 10 12 . Wakame lipids contain about 10 fucoxanthin. Rats fed 0.5 and 2 Wakame-lipid-containing diets lost weight to a significant degree. In addition, Wakame lipid diets decreased WAT and body weight in obese model KK-A y mouse. There was no significant difference in food intake among experimental diets. The same effect was reported for another algae extracts containing fucoxanthin 13 . Furthermore, UCP1 expression was found in WAT when KK-A y mice were fed Wakame lipid containing diets. To confirm the active components of UCP1 expression in WAT, fucoxanthin was purified from Wakame lipids. Then it was fed to KK-A y mice in UCP1 is normally expressed only in brown adipose tissue BAT , not in WAT. BAT is related to energy and heat production in tissues by the contribution of UCP1 14 . UCP1 might reduce excess abdominal fat. Adaptive thermogenesis in BAT is mediated mainly by UCP1, an inner mitochondrial membrane protein that can catalyze the reentry of protons into the mitochondrial matrix, thereby bypassing ATP synthase, uncoupling oxidative phosphorylation, and releasing chemical energy as heat. UCP1 is expressed exclusively in BAT, where the gene expression is increased by cold, adrenergic stimulation, β3-agonists, retinoids, and thyroid hormone Fig. 3 . Thermogenetic activity of BAT is dependent on the UCP1 expression level, which is controlled by the sympathetic nervous system via noradrenalin 14, 15 . In contrast to the scarcity of BAT, almost all adipose tissue in humans is WAT. For that reason, UCP1 expression in WAT is expected to be an attractive target for the development of anti-obesity therapies. Recently, such a low basal expression of UCP1 in white adipocyte is defined as beige adipocyte 16 . The activities of brown and beige fat cells have led to the proposal of a novel therapeutic treatment for obesity. Results showed that fucoxanthin promoted mRNA expressions of β3-adrenergic receptor Adrb3 in WAT 11 .
Adrb3 is regarded as responsible for lipolysis and adaptive thermogenesis through sympathetic nerve stimulation and UCP1 expression. The degree of obesity is correlated with the extent of loss of Adrb3 gene expression in WAT. This result might be related to the effects of fucoxanthin on UCP1 promotion and up-regulation of fat oxidation in WAT. Some researchers have reported clinical experiments to assess fucoxanthin anti-obesity effects. Fucoxanthin 2.4 mg/day was administered to obese women average body weight 100 kg for 16 weeks 17 . The administered fucoxanthin showed significant reduction of body weight, waist circumference, body and liver fat content, and serum triacylglycerol content with a significant increase in resting energy expenditure. This result suggests the involvement of mitochondrial uncoupling UCP1 in the anti-obesity effect of fucoxanthin, which engenders increased resting energy expenditure by uncoupling a step during cellular metabolism in humans. Numerous data have been collected to elucidate thermogenesis in BAT through UCP1 expression. Nevertheless, little information exists in relation to UCP1 expression in WAT induced by a dietary component, with the exception of fucoxanthin.
Anti-diabetic effects of fucoxanthin
Fucoxanthin shows anti-diabetic effects by changing of adipocyte cell properties 11, 12, 18 . KK-A y mice not only developed obesity, but also developed hyperglycemia and hyperinsulinemia along with insulin resistance. The KK-A y mice fed the 0.1 or 0.2 purified fucoxanthin diets had signifi- Furthermore, plasma insulin levels decreased dose-dependently after intake of purified fucoxanthin Fig. 4 B . Anti-obesity and anti-diabetic effects of fucoxanthin were also found in high-fat HF diet-induced obesity in mice 11 .
Fucoxanthin intake significantly suppressed body weight and WAT weight gain induced by the HF diet. Dietary administration of the HF diet increased blood glucose and insulin level, although these levels were ameliorated in the fucoxanthin-containing diet group Figs. 5 A , 5 B .
Increasing the blood glucose level is related to adipocytes in WAT. In actuality, WAT plays an important role as an energy-storage organ and as an endocrine organ, producing adipokines such as monocyte chemoattractant protein-1 MCP-1 , tumor necrosis factor-α TNF-α and Interleukin-6 IL-6 19 . Actually, MCP-1, TNF-α, and IL-6 promote glucose intolerance, dyslipidemia, and high blood pressure. Moreover, MCP-1 induces macrophage infiltration into WAT, and promotes the production of inflammatory cytokines such as TNF-α. In addition, MCP-1 inhibits insulin-dependent glucose uptake and engenders insulin resistance. TNF-α and IL-6 induce insulin resistance in tissues related to glucose homeostasis in organs such as the liver, muscle, and adipose tissue. The overexpression of these adipokines mRNA is attenuated to a marked degree by fucoxanthin in WAT of KK-A y mice and in WAT of C57BL/6J normal mice fed an HF diet 11, 18 . Therefore, down-regulation of MCP-1, TNF-α, and IL-6 mRNA in the WAT of KK-A y mice is expected to be a mechanism underlying the improvement of hyperglycemia by fucoxanthin. Fucoxanthin, hydrolyzed to fucoxanthinol, is partly metabolized to amarouciaxanthin A in internal tissues: liver and adipose tissue 20 Fig. 1 . In KK-A y mice fed 0.1 fucoxanthin diets for 4 weeks, these metabolites were accumulated at 0.85 μg/mg protein and 2.67 μg/mg protein of tissue in the perigonadal WAT, while fucoxanthin was not detected 18 . Dietary fucoxanthin was not affected in food intake same as previous report. Fucoxanthinol reduced MCP-1 and IL-6 mRNA expression in 3T3-F442A adipocyte cells stimulated with TNF-α, which is an inflammatory cytokine produced by both macrophages and adipocytes 18 .
Furthermore, fucoxanthinol was found to prevent TNF-α, inducible nitric oxide synthase iNOS , and cyclooxygenase-2 COX-2 mRNA expressions and protein production of TNF-α in RAW264.7 macrophage-like cells stimulated with palmitic acid. These findings demonstrate that fucoxanthin metabolite directly suppresses the production of pro-inflammatory adipocytokines. In addition to moderating inflammatory in adipocyte cells, fucoxanthin regulates glucose transporter 4 GLUT4 activities in muscle tissues 21, 22 . Skeletal muscle accounts for nearly 40 of base metabolism, playing a noteworthy role in the insulin-induced stimulation of glucose uptake 23 .
GLUT4 translocates into membranes of muscle cells, linked to glucose utilization. However, the translocation is suppressed in an insulin-resistance condition. Moreover, reduction in GLUT4 protein and mRNA levels in skeletal muscle has been reported in high-fat diet cases 24 . The administration of a fucoxanthin-containing diet promoted the recovery of blood glucose uptake to muscle by regulating GLUT4 mRNA expression Fig. 5 C . In this study, GLUT4 mRNA levels were restored in the fucoxanthin-containing diet group compared with control diet group. In KK-A y mice fed 0.2 fucoxanthin diets, GLUT4 translocation in skeletal muscle was recovered compared with that in control mice 22 . In addition, insulin receptor mRNA expression was up-regulated. Phosphorylation of AKT protein, which is related to insulin signaling, was induced in the fucoxanthin-fed group. Further treatment with fucoxanthinol 3T3-L1 adipocyte cells suppress adipocyte differentiation more strongly than those treated with fucoxanthin 25 . Moreover, amarouciaxanthin A suppressed preadipocyte cell differentiation accompanied by peroxisome proliferator-activated receptor γ PPARγ and CCAAT enhancer binding protein α C/EBP α protein expression. That suppressive effect was stronger than that of fucoxanthinol 26 . Fucoxanthin, fucoxanthinol, and amarouciaxanthin A have allenic bonds in their construction. Amarouciaxanthin B, which has similar structure to that of amarouciaxanthin A, however, has no allenic bond. Treatment with amarouciaxanthin B 3T3-L1 adipocyte cells did not show suppressed adipocyte differentiation compared with cells treated with amarouciaxanthin A. Another report described neoxanthin, which is carotenoids containing an allenic bond, show strong effects compared with those of other carotenoids 27 . This result suggests that these physiological functions of fucoxanthin or the metabolites depend on their specific structure.
In conclusion, dietary fucoxanthin contained in algae adjusts adipokine secretion, which is related to inflammation in adipose tissues, further restoring GLUT4 ability in skeletal muscle in a diabetic condition. Recently, other carotenoids, especially xanthophyll, were reported to ameliorate chronic inflammation in adipocytes caused by obesity 28 . Further studies must be done to determine the mechanism for the regulatory effects of these carotenoids on inflammatory mediators related to obesity, insulin resistance, and type-2 diabetes.
Promoting effects of DHA synthesis in liver
Polyunsaturated fatty acids PUFAs such as docosahexaenoic acid DHA and eicosapentaenoic acid EPA have various physiological functions. Dietary DHA and EPA decrease cholesterol and triacylglycerol levels in the blood, thereby preventing cardiac infarction and vascular brain diseases 29, 30 . DHA and EPA are biosynthesized through desaturation and elongation reactions in the body. However, mammals have difficulty biosynthesizing these PUFAs in the body because Δ-6 desaturase is the rate-limiting enzyme in mammalian synthesis of PUFAs. Therefore, mammals must rely on a dietary supply of fish oil as a source of DHA or EPA. Dietary 0.2 fucoxanthin and fucoxanthinol have been shown to enhance the amount of DHA in the liver of KK-A y mice 31 . Few natural compounds have been shown to increase hepatic DHA levels, aside from direct consumption of fish oil. The novel effects of fucoxanthin and fucoxanthinol might contribute beneficial effects for the prevention of lifestyle-related diseases.
Fucoxanthin absorption and safety
Carotenoids are absorbed in the small intestine along with other lipid components of food. For example, α-carotene, β-carotene, lycopene, β-cryptoxanthin, and lutein are detected in high concentrations in human blood 32 . Carotenoid concentrations and species in blood are affected by food. Fucoxanthinol and amarouciaxanthin A have been detected in plasma and tissues of mice with different accumulation ratios 18, 33, 34 . Similarly, after daily intake for 1 week of cooked edible brown seaweed, Undaria pinnatifida Wakame , of 6 g dry weight including 6.1 mg 9.26 mmol of fucoxanthin, fucoxanthinol was detectable at 0.8 pmol/ml in human plasma 20 . In addition, the fucoxanthin absorption rate is affected by other food components, especially lipids. Promoting the rate of the increase in absorption remains unclear, but the combination of fucoxanthin and fish oil, medium-chain triacylglycerol, and scallop phospholipids exerts a beneficial anti-obesity effect 12, 35, 36 .
Fucoxanthin toxicity has arisen as a concern from results of mice experiments 37, 38 . Fucoxanthin was orally administered at doses of 500 and 1,000 mg/kg to male and female ICR mice for 30 days. In this experiment, neither mortality nor histological abnormality was observed. In addition, the mutagenicity of fucoxanthinol was examined using an in vitro Ames test. Mutagenicity of fucoxanthinol was not found in Salmonella typhimurium or Escherichia coli with S9 mix. Moreover, the mutagenicity of fucoxanthin of the micronucleus test in bone marrow cells was examined in in vivo experiments with mice. The differences of micronucleus cells were examined in ICR mice that had been administered 500, 1000, or 2000 mg/kg fucoxanthin. The fucoxanthin-treated group showed no abnormalities of micronucleus cells. These results suggest that fucoxanthin is safe as a component of functional foods in common toxicity assay. Additionally, in eastern Asian countries, sea algae Wakame, Laminaria have been consumed as edible algae for centuries.
Conclusion
Fucoxanthin can be synthesized using chemical methods, but its reaction efficiency is extremely low. Consequently, dilution from natural algae is the most expedient and efficient means to industrialize fucoxanthin. Recently, some companies in Japan have begun to industrialize fucoxanthin as a functional food product. These products are diluted from natural algae such as Saccharina japonica, Nemacystus decipiens Mozuku in Japanese , and Sargassum horneri Turner C. agardh. Additionally, fucoxanthin contents of algae differ among species. Algae containing high concentrations of fucoxanthin are sought as ingredients of commercial products.
Obesity-related diseases pose a severe hazard to public health worldwide. Fucoxanthin has a strong effect on resolving metabolic syndrome problems. That unique effect has not been reported for any other food component. Fucoxanthin in algae is useful as a new functional food from sea products.
